Abstract
The duration of immunity following measles vaccination of 2882 immunized children has been investigated in a closed region of China for 15 years. A total of 1002 of the children were treated as primary immunization subjects, and 1547 as reimmunization subjects. These two cohorts were not in contact with known wild measles virus over the whole observation period, and the results obtained probably reflected the antibody responses to measles vaccine alone. The remaining 333 vaccinees came into contact with wild measles virus, and this permitted evaluation of the protective effect of the measles vaccines tested: 4 children experienced very mild clinical measles, and 329 experienced subclinical infection, including 12 who had had undetectable haemagglutination-inhibition antibodies for 9-10 years. These results indicate that the immunity induced by successful primary immunization may persist for at least 15 years. Within this period, a second dose of vaccine only induces low antibody responses which decrease rapidly to their original levels. This provides strong evidence that the immunity produced by primary immunization is long-lasting. However, there were some indications that reimmunization might produce better effects if live attenuated measles virus were used with a longer interval between doses.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bass J. W., Halstead S. B., Fischer G. W., Podgore J. K., Pearl W. R., Schydlower M., Wiebe R. A., Ching F. M. Booster vaccination with further live attenuated measles vaccine. JAMA. 1976 Jan 5;235(1):31–34. [PubMed] [Google Scholar]
- Black F. L., Berman L. L., Libel M., Reichelt C. A., Pinheiro F. D., Travassos da Rosa A., Figueira F., Siqueira Gonzales E. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ. 1984;62(2):315–319. [PMC free article] [PubMed] [Google Scholar]
- Deseda-Tous J., Cherry J. D., Spencer M. J., Welliver R. C., Boyer K. M., Dudley J. P., Zahradnik J. M., Krause P. J., Walbergh E. W. Measles revaccination. Persistence and degree of antibody titer by type of immune response. Am J Dis Child. 1978 Mar;132(3):287–290. doi: 10.1001/archpedi.1978.02120280071015. [DOI] [PubMed] [Google Scholar]
- Isomura S., Morishima T., Nishikawa K., Hanada N., Rahman M., Terashima M., Kido S., Ueda S., Takahashi M. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine. Biken J. 1986 Mar;29(1):19–26. [PubMed] [Google Scholar]
- Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis. 1983 May-Jun;5(3):477–481. doi: 10.1093/clinids/5.3.477. [DOI] [PubMed] [Google Scholar]
- Linnemann C. C., Jr, Dine M. S., Roselle G. A., Askey P. A. Measles immunity after revaccination: results in children vaccinated before 10 months of age. Pediatrics. 1982 Mar;69(3):332–335. [PubMed] [Google Scholar]
- Miller C. Live measles vaccine: a 21 year follow up. Br Med J (Clin Res Ed) 1987 Jul 4;295(6589):22–24. doi: 10.1136/bmj.295.6589.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pedersen I. R., Mordhorst C. H., Ewald T., von Magnus H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine. 1986 Sep;4(3):173–178. doi: 10.1016/0264-410x(86)90006-x. [DOI] [PubMed] [Google Scholar]